艾美疫苗(06660)股价于2024年10月17日盘中一度大涨近29%,引发市场广泛关注。据悉,推动该股价大涨的主要原因是该公司当日发布公告,称在研的迭代无血清狂苗Ⅲ期临床试验数据已完成揭盲及统计分析工作,结果显示该疫苗具有良好的免疫原性和安全性,达到临床预设目标。
目前全球尚未有无血清狂苗上市,若艾美疫苗顺利上市,该产品将成为首个上市无血清狂苗,引领行业技术深度迭代升级。与目前市场上的含血清狂苗不同,迭代无血清狂苗不含有动物血清,显著提高了安全性,降低了不良反应的概率,属于重磅创新迭代升级产品。
此外,业内人士指出,艾美疫苗当日大涨还受到所属生物医药板块整体向好以及主力机构资金追捧的影响。有分析指出,虽然医药板块曾一度大幅波动,但由于相关公司估值已处历史底部,仍有进一步修复空间,预计未来回暖可能性较大。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.